Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847718 | 0.76 | KDM4E (0.47) | CMA1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1882445 | 0.65 | FGFR1 (0.49) | FGFR1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL1888708 | 0.64 | MEN1 (0.42) | FGFR1KMT2AMEN1MAPTRAB9A | |
| SCHEMBL15435555 | 0.63 | RECQL (0.52) | KMT2AMAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL8561900 | 0.62 | KDM4E (0.56) | KMT2AMEN1MAPTALDH1A1HTT | |
| SCHEMBL15791877 | 0.59 | ERCC1 (0.54) | LMNAALDH1A1HTTMAPK1 | |
| SCHEMBL1882326 | 0.59 | ALDH1A1 (0.53) | CMA1FGFR1KMT2AMEN1MAPT | |
| SCHEMBL15332270 | 0.58 | ERN1 (0.40) | KMT2AMEN1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1883983 | 0.58 | ALDH1A1 (0.43) | FGFR1KMT2AMEN1MAPTRAB9A | |
| Benzene SCHEMBL27733069 | 0.57 | ALDH1A1 (0.65) | KMT2AMEN1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716838-B1 | INHIBITORS OF SERINE PROTEASES OF THE COAGULATION CASCADE | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6458952-B1 | ENZYME INHIBITORS FOR SERINE METHODS FOR PREVENTING AND TREATING THROMBOTIC CONDITIONS SUCH AS CORONARY ARTERY AND CEREBROVASCULAR DISEASE WITH COMPOUNDS THAT INHIBIT SERINE PROTEASES OF THE COAGULATION CASCADE. | PHARMACIA CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1178971-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | TFPI, PLAT, PLAU | CMA1 281/4885FGFR1 2312/4885KMT2A 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.